Catalent’s new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.

Catalent today announced that it has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan, through the installation of a high-speed blister packaging line to complement its existing automated bottling line.

Catalent today announced that company experts will be speaking on current clinical market trends and strategies at two upcoming conferences: Clinical Trial Supply New England; and Clinical Trial Supply Europe.

Catalent today welcomed the recent announcement by Phathom Pharmaceuticals that the U.S. Food and Drug Administration has approved both VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA™ DUAL PAK™ for the treatment of Helicobacter pylori infection in adults.

Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet technology for delivering the MigVax-101 vaccine.

Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.

The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.

Catalent today announced that it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, North Carolina, facility, for the development and manufacturing of unit and bi-dose nasal spray products.

Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.